HC Wainwright Reiterates “Buy” Rating for Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $17.00 price target on the biotechnology company’s stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Curis currently has a consensus rating of “Hold” and an average price target of $17.00.

Curis Price Performance

Shares of NASDAQ:CRIS opened at $0.76 on Friday. The firm’s 50 day simple moving average is $0.98 and its 200 day simple moving average is $1.26. Curis has a fifty-two week low of $0.75 and a fifty-two week high of $3.13. The company has a market capitalization of $10.39 million, a price-to-earnings ratio of -0.21 and a beta of 3.02.

Hedge Funds Weigh In On Curis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CM Management LLC raised its stake in shares of Curis by 47.7% in the 3rd quarter. CM Management LLC now owns 325,000 shares of the biotechnology company’s stock valued at $540,000 after purchasing an additional 105,000 shares during the period. Renaissance Technologies LLC boosted its position in shares of Curis by 37.3% during the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after buying an additional 65,404 shares during the period. Maverick Capital Ltd. grew its holdings in shares of Curis by 7.8% during the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after buying an additional 49,554 shares in the last quarter. Armistice Capital LLC raised its position in Curis by 8.7% in the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 78,265 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its position in Curis by 2,883,237.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 230,659 shares during the last quarter. 29.97% of the stock is owned by institutional investors and hedge funds.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.